Mylan Completes Rights Acquisition of Pfizer LAMA Compound

Mylan (NASDAQ: MYL  ) now officially has a new product in its portfolio. The company announced that it has closed an agreement with Pfizer (NYSE: PFE  ) regarding, and obtained all required regulatory approvals for, a long-acting muscarinic antagonist compound developed by the latter firm. The terms of the deal, as well as more specific information about the compound, are being kept confidential.

LAMAs are used to dilate the passages of the lungs and to relax muscles in order to improve breathing in patients with chronic obstructive pulmonary disease (COPD).

According to the terms of the arrangement, Mylan will hold exclusive commercialization rights for the compound in North America, Australia, New Zealand, the European Union, and member states of the European Free Trade Association, India, and Japan. The company and Pfizer will hold co-promotion rights to the LAMA in the rest of the world.

 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2770469, ~/Articles/ArticleHandler.aspx, 10/2/2014 8:36:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement